Drug Targeting by Diagnostic Ultrasound Contrast - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Drug Targeting by Diagnostic Ultrasound Contrast
Microbubbles can temporarily open many biological barriers for polar molecules, macromolecules, and particles. Scientists have brought well-known contrast agents back to the laboratory and redesigned them as drug carriers.


Pharmaceutical Technology


References

1. C. Mayer and R. Bekeredjian, Adv. Drug Deliv. Rev. 60 (10), 1177–1192 (2008).

2. S. Tinkov et al., J. Pharm. Sci. 98 (6), 1935–1961 (2009).

3. P. Li, W.F. Armstrong, and D.L. Miller, Ultrasound Med. Biol. 30 (1), 83–91 (2004).

4. J. Song et al., J. Am. Coll. Cardiol. 39 (4), 726–731 (2002).

5. M.A. Borden et al., Langmuir 23 (18), 9401–9408 (2007).

6. R. Bekeredjian et al., Circulation 108,1022–1026 (2003).

7. R. Bekeredjian et al., Ultrasound Med. Biol. 31 (5), 687–691 (2005).

8. S. Tinkov et al., J. Control. Release 143 (1), 143–150 (2010).

9. J. Kang, J. Ultrasound Med. 29 (1), 61–70 (2010).

10. E.C. Unger et al., Acad. Radiol. 5 (10), 247–249 (1998).

11. M.S. Tartis et al., Ultrasound Med. Biol. 32 (11), 1771–1780 (2006).

12. J.Y. Fang et al., Eur. J. Pharm. Biopharm. 67 (1), 67–75 (2007).

13. S. Tinkov, Development of Ultrasound Contrast Agents for Targeted Drug and Gene Delivery (Verlag Dr. Hut, Munich, 2009).

14. I. Lentacker, "Design and Evaluation of Drug-Loaded Microbubbles for Ultrasound-Guided Cancer Therapy. Faculty of Pharmaceutical Sciences" (PhD diss., Ghent University, 2009), 216.

15. I. Lentacker et al., Mol. Ther. 18 (1), 101–108 (2010).

16. L.H. Treat et al., Int. J.Cancer 121 (4), 901–907 (2007).

17. R.K. Schlicher et al., Ultrasound Med. Biol. 32 (6), 915–924 (2006).

18. J.R. Eisenbrey et al., J. Control. Release 143 (1), 38–44 (2010).

19. N. Rapoport, Z. Gao, and A. Kennedy, J. Natl. Cancer Inst. 99 (14), 1095–1106 (2007).

20. J.J. Choi, "Noninvasive, Localized, and Transient Brain Drug Delivery Using Focused Ultrasound and Microbubbles" (PhD diss., University of Columbia, 2010), 170.

21. E.E. Konofagou et al., AIP Conference Proceedings (Aix-en-Provence, France, 2010), pp. 172–175.

22. J.M. Erikson, G.L. Freeman, and B. Chandrasekar, J. Mol. Cell. Cardiol. 35 (1), 119–130 (2003).

23. E. Akowuah et al., Gene Ther. 12 (14), 1154–1157 (2005).

24. T.R. Porter et al., Ultrasound Med. Biol. 27 (2), 259–265 (2001).

25. X. Feng et al., Ultrasound Med. Biol. 31 (7), 979–985 (2005).

26. F.M. Asch and N.J. Weissman, Circulation 119 (14), 1956–1961 (2009).

27. S. Seemann et al., Pharm. Res. 19 (3), 250–257 (2002).

28. K. Kooiman et al., J. Control. Release 133 (2), 109–118 (2009).

29. A. Kheirolomoom et al., J. Control. Release 118 (3), 275–284 (2007).

30. M.L. Fabiilli, Ultrasound Medicine Biol. 36 (8), 1364–1375 (2010).

31. K.H. Nam et al., AIP Conference Proceedings (Aix-en-Provence France, 2009), pp. 124–128.

32. S.L. Huang and R.C. MacDonald, Biochim. Biophys. Acta 1665 (1–2), 134–141 (2004).

33. S. Tinkov et al., J. Pharm. Sci. 98 (6), 1935–1961 (2009).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
32%
Breakthrough designations
8%
Protecting the supply chain
40%
Expedited reviews of drug submissions
8%
More stakeholder involvement
12%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here